"To see this level of benefit for patients who have endured numerous treatments is incredibly encouraging. This could represent a real shift in how we treat head and neck cancer not just in terms of effectiveness, but also in how we deliver care. He added: This is the first time we've tested this kind of triple-action therapy for head and neck cancer patients whose disease has returned after treatment."
"Amivantamab is a smart drug that not only blocks two key cancer pathways but also helps the immune system do its job. Unlike many cancer treatments that require hours in a hospital chair, amivantamab is given as a simple injection under the skin. This makes it faster, more convenient, and potentially easier to deliver in outpatient clinics or even at home in the future."
Amivantamab, a triple-action targeted antibody, blocks two cancer-signalling pathways and enhances immune response while being delivered as a subcutaneous injection. The Orig-AMI 4 trial enrolled patients from 11 countries with recurrent or metastatic head and neck squamous cell carcinoma who had previously received immunotherapy and platinum chemotherapy. In a cohort of 86 heavily pretreated patients, amivantamab induced tumour shrinkage within six weeks. The subcutaneous route reduces administration time compared with many intravenous treatments, enabling faster outpatient delivery and potential home administration. The trial was funded by Janssen.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]